Nimesulide
On 15 May 2007, the Irish Medicines Board announced the suspension of all medicinal products containing the drug Nimesulide in Ireland with immediate effect.
Affected products
The products affected by the suspension are:
| Product Name | Marketing Authorisation Number |
|---|---|
| Aulin 100mg Tablets | PA 294/18/1 |
| Aulin 100mg Granules | PA 294/18/2 |
| Mesulid 100mg Granules | PA 915/1/1 |
| Mesulid 100mg Tablets | PA 915/1/2 |
| Mesine 100mg Tablets | PA 281/111/1 |
| Aulin 100mg Tablets | PPA 465/110/1 |
| Aulin 100mg Granules | PPA 1328/51/1 |
| Aulin 100mg Tablets | PPA 1328/51/2 |
Nimesulide is a non-steroidal anti-inflammatory drug (NSAID) that was first marketed in Ireland in 1995. It was prescribed to treat acute pain, osteoarthritis and primary dysmenorrhea (period pain). Until its withdrawal in May, there were approx 30,000 prescriptions of Nimesulide written in Ireland per month.
It has emerged that Nimesulide can cause liver and kidney damage in patients and a COHORT study into the drug concluded the following:
- Nimesulide increases the risk of adverse hepatic consequences by 30% in patients with NO HISTORY of liver or renal problems
- Nimesulide increases the risk of adverse hepatic consequences by 90% in patients who have a history of liver or renal problems
Making a claim
Malcomson Law have taken a number of enquiries from persons who believe that they have suffered from the adverse side effects of Nimesulide.
For further information, please contact Malcomson Law by calling 01 8744422 or complete an Online Enquiry Form. A solicitor who specialises in product liability and pharmaceutical litigation will contact you to advise you of your legal rights and entitlements.